Sinomenine inhibits A549 human lung cancer cell invasion by mediating the STAT3 signaling pathway

Jiang,Shulong; Gao,Yebo; Hou,Wei; Liu,Rui; Qi,Xin; Xu,Xia; Li,Jie; Bao,Yanju; Zheng,Honggang; Hua,Baojin

doi:10.3892/ol.2016.4768

Sinomenine inhibits A549 human lung cancer cell invasion by mediating the STAT3 signaling pathway

Authors:
- Shulong Jiang
- Yebo Gao
- Wei Hou
- Rui Liu
- Xin Qi
- Xia Xu
- Jie Li
- Yanju Bao
- Honggang Zheng
- Baojin Hua
View Affiliations

Affiliations: Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, P.R. China, Department of Oncology, Jining First People's Hospital, Jining, Shandong 272111, P.R. China
Published online on: June 23, 2016 https://doi.org/10.3892/ol.2016.4768
Pages: 1380-1386
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence suggests that the failure of lung cancer treatment may occur as a result of tumor invasion and metastasis. Signal transducer and activator of transcription 3 (STAT3), an epithelial-mesenchymal transition-inducing transcription factor, is a key signaling molecule involved in the proliferation, apoptosis, invasion and metastasis of tumor cells. Sinomenine is an alkaloid compound with an antineoplastic potential against a variety of cancer cells. The aim of the present study was to assess the antitumor mechanisms of sinomenine in the A549 human lung cancer cell line. The results demonstrated that sinomenine manifested dose‑dependent cytotoxicity and induced apoptosis in A549 cells. The protein expression of Janus kinase 2, STAT3, phosphorylated‑STAT3, Snail, N‑cadherin and vimentin decreased in sinomenine‑treated cells, while E-cadherin protein expression increased. The regulation of STAT3, N‑cadherin and E‑cadherin by sinomenine was further confirmed by reverse transcription‑quantitative polymerase chain reaction and immunofluorescent staining. It was demonstrated that sinomenine exerts inhibitory effects on A549 human lung cancer cell invasion, possibly through the inhibition of STAT3 signaling. These results provide a novel insight into the role of sinomenine in the treatment of non-small cell lung cancer.

View Figures

View References

1	Yano T, Okamoto T, Fukuyama S and Maehara Y: Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin Oncol. 5:1048–1054. 2014. View Article : Google Scholar : PubMed/NCBI
2	Pirker R: Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. Transl Lung Cancer Res. 3:305–310. 2014.PubMed/NCBI
3	Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L: International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714. 2007. View Article : Google Scholar : PubMed/NCBI
4	Byron E and Pinder-Schenck M: Systemic and targeted therapies for early-stage lung cancer. Cancer Control. 21:21–31. 2014.PubMed/NCBI
5	Akbari-Birgani S, Paranjothy T, Zuse A, Janikowski T, Cieślar-Pobuda A, Likus W, Urasińska E, Schweizer F, Ghavami S, Klonisch T and Łos MJ: Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discov Today. 21:836–842. 2016. View Article : Google Scholar : PubMed/NCBI
6	Brower V: Back to nature: Extinction of medicinal plants threatens drug discovery. J Natl Cancer Inst. 100:838–839. 2008. View Article : Google Scholar : PubMed/NCBI
7	Li JW and Vederas JC: Drug discovery and natural products: End of an era or an endless frontier? Science. 325:161–165. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhu Q, Sun Y, Zhu J, Fang T, Zhang W and Li JX: Antinociceptive effects of sinomenine in a rat model of neuropathic pain. Sci Rep. 4:72702014. View Article : Google Scholar : PubMed/NCBI
9	Qian L, Xu Z, Zhang W, Wilson B, Hong JS and Flood PM: Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation. 4:232007. View Article : Google Scholar : PubMed/NCBI
10	Kok TW, Yue PY, Mak NK, Fan TP, Liu L and Wong RN: The anti-angiogenic effect of sinomenine. Angiogenesis. 8:3–12. 2005. View Article : Google Scholar : PubMed/NCBI
11	Li XJ, Yue PY, Ha WY, Wong DY, Tin MM, Wang PX, Wong RN and Liu L: Effect of sinomenine on gene expression of the IL-1 beta-activated human synovial sarcoma. Life Sci. 79:665–673. 2006. View Article : Google Scholar : PubMed/NCBI
12	Jiang T, Zhou L, Zhang W, Qu D, Xu X, Yang Y and Li S: Effects of sinomenine on proliferation and apoptosis in human lung cancer cell line NCI-H460 in vitro. Mol Med Rep. 3:51–56. 2010.PubMed/NCBI
13	Lu XL, Zeng J, Chen YL, He PM, Wen MX, Ren MD, Hu YN, Lu GF and He SX: Sinomenine hydrochloride inhibits human hepatocellular carcinoma cell growth in vitro and in vivo: Involvement of cell cycle arrest and apoptosis induction. Int J Oncol. 42:229–238. 2013.PubMed/NCBI
14	Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008. View Article : Google Scholar : PubMed/NCBI
15	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kuraishy A, Karin M and Grivennikov SI: Tumor promotion via injury- and death-induced inflammation. Immunity. 35:467–477. 2011. View Article : Google Scholar : PubMed/NCBI
17	Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
18	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
19	He G and Karin M: NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res. 21:159–168. 2011. View Article : Google Scholar : PubMed/NCBI
20	Bosch-Barrera J and Menendez JA: Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev. 41:540–546. 2015. View Article : Google Scholar : PubMed/NCBI
21	Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
22	Wu Y, Ma G, Lu D, Lin F, Xu HJ, Liu J and Arlinghaus RB: Bcr: A negative regulator of the Bcr-Abl oncoprotein. Oncogene. 18:4416–4424. 1999. View Article : Google Scholar : PubMed/NCBI
23	Liu Z, Duan ZJ, Chang JY, Zhang ZF, Chu R, Li YL, Dai KH, Mo GQ and Chang QY: Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression. PLoS One. 9:e985602014. View Article : Google Scholar : PubMed/NCBI
24	Li X, Wang K, Ren Y, Zhang L, Tang XJ, Zhang HM, Zhao CQ, Liu PJ, Zhang JM and He JJ: MAPK signaling mediates sinomenine hydrochloride-induced human breast cancer cell death via both reactive oxygen species-dependent and -independent pathways: An in vitro and in vivo study. Cell Death Dis. 5:e13562014. View Article : Google Scholar : PubMed/NCBI
25	Zhang JX, Yang ZR, Wu DD, Song J, Guo XF, Wang J and Dong WG: Suppressive effect of sinomenine combined with 5-fluorouracil on colon carcinoma cell growth. Asian Pac J Cancer Prev. 15:6737–6743. 2014. View Article : Google Scholar : PubMed/NCBI
26	Spitzner M, Ebner R, Wolff HA, Ghadimi BM, Wienands J and Grade M: STAT3: A novel molecular mediator of resistance to chemoradiotherapy. Cancers (Basel). 6:1986–2011. 2014. View Article : Google Scholar : PubMed/NCBI
27	Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
28	Ishida F, Matsuda K, Sekiguchi N, Makishima H, Taira C, Momose K, Nishina S, Senoo N, Sakai H, Ito T and Kwong YL: STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci. 105:342–346. 2014. View Article : Google Scholar : PubMed/NCBI
29	Geletu M, Guy S and Raptis L: Effects of SRC and STAT3 upon gap junctional, intercellular communication in lung cancer lines. Anticancer Res. 33:4401–4410. 2013.PubMed/NCBI
30	Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R and Sarin SK: From cirrhosis to hepatocellular carcinoma: New molecular insights on inflammation and cellular senescence. Liver Cancer. 2:367–383. 2013. View Article : Google Scholar : PubMed/NCBI
31	Hsu FN, Chen MC, Lin KC, Peng YT, Li PC, Lin E, Chiang MC, Hsieh JT and Lin H: Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells. Am J Physiol Endocrinol Metab. 305:E975–E986. 2013. View Article : Google Scholar : PubMed/NCBI
32	Ibrahim SA, Hassan H, Vilardo L, Kumar SK, Kumar AV, Kelsch R, Schneider C, Kiesel L, Eich HT, Zucchi I, et al: Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One. 8:e857372013. View Article : Google Scholar : PubMed/NCBI
33	Zhao Y, Li J, Yu K, Liu Y and Chen X: Sinomenine inhibits maturation of monocyte-derived dendritic cells through blocking activation of NF-kappa B. Int Immunopharmacol. 7:637–645. 2007. View Article : Google Scholar : PubMed/NCBI
34	De Simone V, Franzè E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, et al: Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-κB to promote colorectal cancer cell growth. Oncogene. 34:3493–3503. 2015. View Article : Google Scholar : PubMed/NCBI
35	Levy DE and Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol. 3:651–662. 2002. View Article : Google Scholar : PubMed/NCBI
36	Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Kim CH and Lee JC: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer. 63:219–226. 2009. View Article : Google Scholar : PubMed/NCBI
37	Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M and Allgayer H: Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res. 8:1207–1216. 2010. View Article : Google Scholar : PubMed/NCBI
38	Micalizzi DS, Farabaugh SM and Ford HL: Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
39	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
40	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
41	Yadav A, Kumar B, Datta J, Teknos TN and Kumar P: IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
42	Peinado H, Portillo F and Cano A: Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 48:365–375. 2004. View Article : Google Scholar : PubMed/NCBI
43	Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI